Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program

Affiliation auteurs!!!! Error affiliation !!!!
TitreReal-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
Type de publicationJournal Article
Year of Publication2021
AuteursBertho M, Fraisse J, Patsouris A, Cottu P, Arnedos M, Perol D, Jaffre A, Goncalves A, Lebitasy M-P, D'Hondt V, Dalenc F, Ferrero J-M, Levy C, Dabakuyo S, Rouzier R, Penault-Llorca F, Uwer L, Eymard J-C, Breton M, Chevrot M, Thureau S, Petit T, Simon G, Frenel J-S
JournalTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume13
Pagination1758835920987657
Date PublishedJAN
Type of ArticleArticle
ISSN1758-8340
Mots-clésbone-only, Metastatic breast cancer, outcomes, Overall survival, Real-life, Treatments
Résumé

{Background: Bone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far. Methods: Using the French national multicenter ESME (Epidemiological Strategy and Medico Economics) Data Platform, the primary objective of our study was to compare the overall survival (OS) of patients with BO versus non-BO MBC at diagnosis, with adjustment on main prognostic factors using a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1), describe treatment patterns, and estimate factors associated with OS. Results: Out of 20,095 eligible women, 5041 (22.4%) patients had BO disease [hormone-receptor positive (HR+)/human epidermal growth-factor-receptor-2 negative (HER2-)
DOI10.1177/1758835920987657